BioAge Stock Nosedives On Obesity Drug Study Halt

BioAge Stock Nosedives On Obesity Drug Study Halt: Downgrades Crush Retail Sentiment
BioAge Labs’ stock lost more than two-thirds of its market cap in pre-market trading Monday, poised to hit an all-time low following its decision to discontinue the STRIDES Phase 2 study of azelaprag,
Richmond-based BioAge sees stock fall over 70% after halting obesity drug clinical trial
After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70% after shelving an obesity drug.
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns
In the trail, 11 participants in the azelaprag group exhibited transaminase elevations without significant symptoms.
BioAge shares tumble after decision to halt obesity drug study
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following safety concerns.
BioAge stock craters 70% on obesity drug study halt (update)
Shares of BioAge (NASDAQ:BIOA) cratered 75% Friday in post-market trading after the company said it was discontinuing a Phase 2 study for its weight-loss drug azelaprag over safety concerns. The study had been evaluating azelaprag as both a monotherapy and in combination with Eli Lilly’s (LLY) tirzepatide,
BioAge scraps mid-stage trial of experimental obesity drug
BioAge Labs said on Friday it is discontinuing the mid-stage trial of its experimental obesity drug after high levels of certain liver enzymes were observed
BioAge Labs, Inc. Being Investigated on Behalf of BioAge Labs, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, ...
FierceBiotech3d
BioAge's phase 2 obesity study derailed by liver side effects 2 months after IPO
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
BioSpace3d
BioAge Crashes After Axing Phase II Obesity Study
The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational ...
BioAge Shares Slide Premarket After Obesity Study Halted for Safety
Shares of BioAge Labs plunged nearly 70% in premarket trading Monday after the clinical-stage biopharmaceutical company said it was ending a mid-stage study of its lead program, a proposed obesity ...
The Pharma Letter3d
BioAge's chances slimmer after obesity failure
Monday looks likely to be a tough day for BioAge Labs, a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.
BioAge Labs Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / December 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...